Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $378.44 Average PT from Brokerages
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation […]
